Best of ASCO - 2014 Annual Meeting

 

Welcome

Central Nervous System Tumors

Central Nervous System Tumors

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A large, multicenter, retrospective study to identify a cutoff of MGMT methylation status by quantitative pyrosequencing approach in patients (PTS) with glioblastoma (GBM).

Giuseppe Lombardi

2012

A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).

Michael Platten

2001

A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.

Daniela Annenelie Bota

e14083

A phase I expansion study of pegargiminase, cisplatin, and pemetrexed in argininosuccinate synthetase 1-negative recurrent high grade gliomas (HGGs).

Peter Edward Hall

e14085

A phase I/II clinical trial of autologous CMV-specific cytotoxic T cells (CMV-TC) for glioblastoma: Dose escalation results.

Marta Penas-Prado

2035

A phase II study of subcutaneous bevacizumab for recurrent glioblastoma: Roadblocks and promises.

Joseph Quillin

e14089

A phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma.

Narayan Adhikari

e14088

A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.

Laura Donovan

TPS2073

A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).

Mustafa Khasraw

2045

A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.

John Frederick De Groot

TPS2071

A unique MRI-based radiomic signature predicts hypermutated glioma genotype.

Islam Hassan

2022

About safety of neuroprotectors in malignant brain tumors.

Eduard Evgenevich Rostorguev

e14079

Actionable targets involving FGF receptors in gliomas: Molecular specificities, spatial distribution, clinical outcome and radiological phenotype.

Anna Luisa Di Stefano

2005

ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.

Mehdi Touat

2003

Angiotensinogen gene silencing to predict bevacizumab response in recurrent glioblastoma patients.

Thomas Urup

2027

Association between treatment facility volume and mortality in patients with glioblastoma (GBM): A large national analysis.

Sonikpreet Aulakh

2026

Association between VTE and MGMT status in patients with high grade glioma.

Angela Aziz-Donnelly

e14055

Association of anticonvulsant prophylaxis in patients with primary and metastatic brain tumors and 1-year overall survival: A systematic review and meta-analysis.

Timothy J Brown

2043

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Emilie Le Rhun

e14070

Binocular radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.

Macarena Ines De La Fuente

e14059

CD38-targeted therapy in glioblastoma: A step forward.

Sonikpreet Aulakh

e14030

Characterization of clinically aggressive meningiomas by mutational signatures associated with DNA mismatch repair and aging.

Sylvia Christine Kurz

e14044

Choroid plexus tumors of the central nervous system: Searching for therapy targets with comprehensive genomic profiling.

Robert John Corona

e14084

Clinico-epidemiologic characteristics and patterns of care in glioblastoma multiforme: Data from a single-institution series.

Andrew Samir Iskandar

e14069

Clinico-pathologic features and survival in elderly patients vs. older and younger adults with glioblastoma multiforme: An exploratory analysis of a series of consecutive patients.

Andrew Samir Iskandar

e14071

C-Methionine PET (Met-PET) for a diagnosis algorithm for pseudoprogression (PsP), radiations necrosis (RN) and progression (P) after an indeterminate magnetic resonance imaging (MRI) in glioblastoma (GBM).

Eudald Felip-Falg s

e14039

CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against CMV-positive tumors.

David E Anderson

e14032

Community socioeconomic status to identify higher-risk patients with malignant glioma.

Aaron Stephen Bower

2060

Comparative gene expression analysis for identifying clinically relevant overexpressed genes in childhood brain tumors.

Lauren Sanders

e14033

Comparison of genomic profiles to reveal heterogenous patterns of tumor evolution in primary and recurrent diffuse gliomas.

Libuse Lizcova

e14060

Comprehensive evaluation on treatment and outcomes of grade II diffuse gliomas.

Catherine R. Garcia

e14025

Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas.

Lee A. Albacker

2039

Concordance between RTOG and EORTC risk factors in low grade gliomas: Who will remain standing in the ring at bell’s sound?

Enrico Franceschi

2040

Consolidative high dose chemotherapy and autologous stem cell transplant for patients with primary central nervous system lymphoma using thiotepa, busulfan, and cyclophosphamide conditioning regimen.

Patricia Ann Young

e14077

Contrast enhancement as a prognostic factor in IDH1/2 mutant glioma.

Bogdana Suchorska

2029

Correlation of genomic copy number variation with survival outcomes in high-grade glioma patients.

Zachary Buchwald

e14091

Correlation of immune infiltration of cytotoxic T cells and activated microglia in glioblastoma (GBM) post anti-PD1 therapy with response.

Andrew Silverman

2055

CXCR4 blockade at the end of irradiation to improve local control of glioblastoma (GBM).

Reena Parada Thomas

2019

Depression and survival of glioma patients: A systematic review and meta-analysis.

Nayan Lamba

2025

Development of a prognostic model for glioblastoma patients treated with standard therapy: A prospective study from a single institution.

Hans Skovgaard Poulsen

e14086

Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.

Kent C. Shih

2061

Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.

Michael Weller

2013

Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine.

David A. Reardon

2020

Effect of therapeutic pressure on stability of EGFR amplification in glioblastoma.

Manmeet Singh Ahluwalia

2033

Effect of time interval between surgery and radiation therapy initiation in glioblastoma patients on overall survival.

Mahadev Potharaju

e14047

EGFR alterations in gliosarcoma: A single institution experience.

Ashley Woods

e14022

Evaluation of the significance of TERT mutations in the presence of NF1 mutations in high grade glioma.

Evangelia Razis

e14058

Feasibility and benefit of molecularly-informed enrollment into early phase trials for patients with recurrent gliomas.

Capucine Baldini

2004

First in human phase I study of chlorogenic acid injection in recurrent high grade glioma.

Wenbin Li

e14081

GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.

Wolfgang Wick

2000

GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotonib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB): Results of the dose-escalation phase.

Maria Martinez Garcia

2054

Gene expression profiling to identify new prognostic markers in glioma.

Elise Deluche

e14054

Genomic landscape of pineoblastoma.

Bryan Kincheon Li

2028

Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.

Dorothee Gramatzki

e14062

Health care utilization and end of life care in patients with primary malignant brain tumors.

Sunil Mahesh Bhatt

e14072

How far have we really come? Trends in survival and mortality for gliomas between 1973 to 2014 from SEER.

Shehryar Rahim Sheikh

2038

Hypofractionated accelerated radiotherapy (HART) with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM).

Supriya Mallick

e14090

Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.

Damien Pouessel

2046

IDH-wild type low grade gliomas: An AINO (Italian Association of Neuro-Oncology) retrospective study.

Roberta Ruda

2050

IDO1 expression in glioma molecular subtypes.

James Snyder

e14029

Immunological evaluation of peptides in pediatric medulloblastomas and diffuse intrinsic pontine glioma (DIPG).

Juan Pablo Marquez-Manriquez

e14066

Improved prognostic accuracy of alternative MGMT methylation status cutpoint: A single institution experience.

Jacob Easaw

2052

Incidental meningiomas: Validation of a novel scoring system to stratify risk for progression.

David Olayinka Kamson

e14024

Integrated clinical experience with ONC201 in H3 K27M glioma.

Andrew S. Chi

2059

Interrogating machine learning classifiers and dimensionality reduction techniques for radiomic prediction of glioma tumor grade.

Kareem Wahid

2031

Intratumoral activity of ONC201 in adult recurrent glioblastoma patients.

Isabel Arrillaga

e14034

Lenalidomide as treatment for relapsed or refractory primary CNS lymphoma: A single institutional experience.

Donna M Molaie

e14036

Long-term stroke risk of single-fraction photon-based stereotactic radiosurgery for meningioma.

Shearwood McClelland

2021

Meningioma: Association of mean and "hot spot" MIB1 with grade.

Christopher Dardis

2030

Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial.

Nataniel Hernan Lester-Coll

e14046

Molecular and neuro-radiological characteristics of diffuse grade II and III gliomas involving the insula.

Emeline Tabouret

e14050

Molecular profile of glioblastoma as perspective of targeted therapy.

Georgy M. Manikhas

e14037

MRI contrast enhancement (CE): Analysis as survival prognostic factor in low grade gliomas (LGG).

Enrique Alanya Rodríguez

e14031

MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.

Michael White

e14041

Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.

Lakshmi Nayak

2037

NKG2D chimeric antigen receptor-T cells to target GBM.

Hong-jiu Dai

2034

Non-invasive determination of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status in glioblastoma (GBM) using magnetic resonance imaging (MRI).

Saima Rathore

2051

NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.

Andrew E. Sloan

2053

Pattern of care and outcome of ederly patients with glioblastoma: Preliminary analysis of the Timone Cohort.

Laetiita Padovani

e14065

Patterns of care and outcomes for glioblastoma in patients with poor performance status.

Nikita Malakhov

e14093

Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors.

Jason D. Lickliter

e14048

Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.

Ingo K. Mellinghoff

2002

Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.

Howard Colman

2015

Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.

David M. Peereboom

2058

Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.

Anthony J. Chalmers

2018

Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma.

Stefania Maraka

2044

Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).

Frank Saran

2036

Phase I/II study of laser interstitial thermotherapy (LITT) combined with checkpoint inhibitor for recurrent glioblastoma (rGBM).

Andrew E. Sloan

TPS2074

Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.

David A. Reardon

2006

Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.

Eudocia Quant Lee

2032

Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.

Manmeet Singh Ahluwalia

2041

Plasma cell-free DNA (cfDNA) concentration and radiographic tumor burden in patents with glioblastoma (GBM).

Stephen Joseph Bagley

2048

Plasminogen regulators could be markers of malignancy for brain tumors.

Eduard Evgenevich Rostorguev

e14074

Preclinical studies of BMI-1 modulator PTC596 in diffuse intrinsic pontine gliomas, pediatric high-grade gliomas and medulloblastoma.

Shiva Senthil Kumar

e14051

Preliminary report of a multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: An NF Clinical Trials Consortium study.

Scott Randall Plotkin

2056

Preoperative and non-invasive prediction of chromosome arm 1p/19q codeletion in oligodendroglial tumors using MRI-based radiomics.

Jingwei Wei

2049

Primary and secondary gliosarcomas: A review of clinical features and pathological diagnosis.

Jinghui Liu

e14043

Prognostic and functional characterization of AQP1 and AQP4 in patients with glioma.

Meihua Chen

e14063

Prospective analysis of cancer stem cell drug response assay for glioblastoma patients.

Tulika Ranjan

2057

Randomized feasibility study of temozolomide chronotherapy for high grade glioma.

Jian Li Campian

e14035

Randomized study of conventional versus hypo-fractionated radiotherapy in diffuse intrinsic pontine glioma.

Yousra Izzuddeen

e14075

Safety and preliminary efficacy data from a phase I study of an implantable low intensity pulsed ultrasound (LIPU) device for disrupting the blood-brain barrier (BBB) in patients treated by chemotherapy for recurrent glioblastoma (GBM).

Ahmed Idbaih

2016

Safety of axitinib plus avelumab in patients with recurrent glioblastoma.

Laila Ben Salama

e14082

Safety of intra-arterial chemotherapy with osmotic opening of the blood brain barrier.

Jenny Firkins

e14056

Safety of tumor treating fields and concomitant radiotherapy for newly diagnosed glioblastoma.

Rachel Grossman

e14078

Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.

Emilie Le Rhun

2042

Sensitization of glioblastoma to alkylating chemotherapy by ultrasound-mediated delivery of therapeutic liposomes.

Patrick Roth

e14061

TERT rearrangements to identify a subset of aggressive meningiomas.

Tareq A. Juratli

e14028

Tetanus toxoid pre-conditioning in recurrent glioblastoma treated with dendritic cell immunotherapy is associated to CD8+ T cell response.

Marica Eoli

e14053

The natural course of hypermutator gliomas.

Carlos Kamiya-Matsuoka

2014

Third-line therapy in glioblastoma: Analysis of a single centre database.

Enrico Franceschi

e14057

Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).

Giuseppe Lombardi

2047

Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).

Martin J. Van Den Bent

2023

Vascular endothelial growth factor A as a marker of bevacizumab in glioblastoma.

Weir Chiang You

e14068

VXM01 phase I study in patients with progressive glioblastoma: Final results.

Wolfgang Wick

2017

White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.

Fayez Estephan

e14038

Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma.

John Frederick De Groot

2008